CN102552142A - Liposome preparing method suitable for industrial production - Google Patents
Liposome preparing method suitable for industrial production Download PDFInfo
- Publication number
- CN102552142A CN102552142A CN201110454185XA CN201110454185A CN102552142A CN 102552142 A CN102552142 A CN 102552142A CN 201110454185X A CN201110454185X A CN 201110454185XA CN 201110454185 A CN201110454185 A CN 201110454185A CN 102552142 A CN102552142 A CN 102552142A
- Authority
- CN
- China
- Prior art keywords
- liposome
- injection
- aquation
- organic solvent
- dissolved
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention aims at providing a liposome preparing method suitable for industrial production. The liposome preparing method provided by the invention comprises the following steps of: dissolving a fat-soluble chemical constituent in an organic solvent and a carrier in an aqueous phase, dropwise adding a carrier solution to the organic solvent under the condition of water-bath magnetic force stirring, reducing the pressure to remove the organic solvent and water content, decreasing grain sizes under the action of additional applied force after redissolving by using a hydration medium, adding a freeze-drying protective agent for freeze drying to obtain liposome powder, and redissolving to obtain a liposome solution before use. According to the liposome preparing method, the liposome is prepared by using a pressure reduction carrier free-drying technology so that the stability of the liposome can be substantially increased; and the preparing method facilitates the large-scale production, thereby a new thinking for the industrial production of the liposome is provided.
Description
Technical field
Technical field of the present invention relates to the design and the preparation of novel pharmaceutical formulation, and a kind of method for preparing lipidosome of suitable suitability for industrialized production is provided.
Background technology
Liposome has slow release, targeting, raising medicine stability and improves advantages such as pharmacokinetic properties, is one of focus of nearly 20 years domestic and international novel drug-supplying system research fields.Because liposome when being delivered to tumor vessel, can getting into tumor tissues through capillary tube epithelial tissue gap, thereby reach certain tumor tissues targeting.The passive target effect of liposome drug-loading system distributes because of it has changed in the body of medicine, thus can when improving curative effect, reduce toxicity, as the good carrier that improves the medicine drug loading.Through the application of liposome, good solution the low problem of insoluble drug dissolubility, played the reduction toxic reaction, eliminate the effect of side reaction, higher targeting distribution character is arranged.So liposome as novel transmission system, is occupying an important position aspect the research and development of injection cancer therapy drug.Yet the listing product of external Liposomal formulation is still very few so far; At home, except the substrate of indivedual external preparation, liposome research is in laboratory stage basically.Main cause is: (1) liposome turbid liquor is prone to assemble at lay up period, fusion and drug leakage, and especially the seepage of water soluble drug is more remarkable; Simultaneously, natural phospholipid is prone to oxidation, hydrolysis, is difficult to satisfy the requirement of pharmaceutical preparation stability; (2) preparation technology of Liposomal formulation is complicated, is difficult for enlarging producing.Method for preparing lipidosome commonly used has film dispersion method and alcohol injection; The former is difficult to enlarge production; The latter has serious dissolvent residual problem, and the liquid towards liposome carries out lyophilization can alleviate storage stability to a certain extent, but complex process, cost are high.
Summary of the invention
The invention provides a kind of novel method for preparing of Injectable liposomal; Its preparation technology can degerming remove thermal source, need not special installation, is beneficial to amplification; Production time is short; Be easy to suitability for industrialized production more, improved the stability of medicine and adjuvant, for extensive patients provides the injection freeze-dried lipidosome preparation of safety and stability more.
The present invention prepares through following equipment:
The three neck round-bottomed flasks that rhombohedral rotor is housed are positioned in the magnetic agitation water-bath.Three mouths of three neck round-bottomed flasks are connected with respectively like lower device: the left side mouth is a vacuum orifice 1; The centre is a charge door 2, is connected with charging hopper when reinforced, seals with plug during preparation; The right side is a discharging opening 3, seals with plug during preparation.Equipment drawing is seen Fig. 1.
Preparation technology is following:
1, carrier is dissolved in water for injection, and medicine, matrix material and stabilizing agent are dissolved in organic solvent, adds the activated carbon filtration depyrogenation respectively;
2,, under the condition of magnetic agitation, the water for injection that is dissolved with carrier material is joined in the organic solvent that is dissolved with medicine and matrix material gradually at 20-70 ℃;
3,, under the condition of magnetic agitation, organic solvent and water for injection are removed in 2 decompressions at 20-70 ℃; Add the aquation medium aquation that contains emulsifying agent then; Particle diameter through the solution after the applied external force reduction aquation through 0.22 μ m membrane filtration degerming, obtains uniform liposome solutions;
4, add freeze drying protectant with 3, remove moisture, obtain exsiccant 7-ethyl-10-hydroxycamptothecine lipidosome freeze-dried injection, be recovered to liposome, drug administration by injection after the aquation jolting before using through lyophilization.
Wherein, carrier is selected from sodium chloride, glucide, as: one or more in glucose, sucrose, mannitol, the sorbitol etc.
Matrix material is a phospholipid, is selected from one or more mixture in sphingomyelin, phosphatidylcholine, Phosphatidylserine, the cuorin.
Stabilizing agent is selected from butylated hydroxyarisol, 2,6-di-t-butyl hydroxy-methylbenzene, nitrogen, alpha-tocopherol, one or more mixture in α-tocopheryl acetate, the dilauryl thiodipropionate etc.
Emulsifying agent is selected from poloxamer, one or more mixture in polyoxyethylene hydrogenated Oleum Ricini, Tweens, the spans etc.
Freeze drying protectant is a glucide, as: one or more in lactose, mannitol, sorbitol, xylitol, sucrose, trehalose, dextran, the polyvinylpyrrolidone (PVP) etc.
Method for preparing of the present invention is for can all being suitable for the medicine that film dispersion method prepares liposome.
Description of drawings:
Fig. 1 is the equipment drawing of preparation of the present invention.
The specific embodiment:
It below is the instantiation that is prepared as of lipidosome freeze-dried injection.
Embodiment one:
1) the 1kg glucose transporter is dissolved in 2L water for injection, and 10g7-ethyl-10-hydroxycamptothecine, 200g soybean lecithin and 0.01 μ moL/mL alpha-tocopherol are dissolved in 20L ethanol, add 1% activated carbon filtration depyrogenation respectively;
2), under the condition of magnetic agitation, the water for injection that is dissolved with carrier material is joined in the organic solvent that is dissolved with medicine and matrix material gradually at 20 ℃;
3) at 20 ℃; Under the condition of magnetic agitation; With 2) reduce pressure and remove organic solvent and water for injection, add the sodium hydroxide-phosphate buffer solution 10L aquation that contains the 1g poloxamer then, through the particle diameter of the solution after the ultrasonic wave concussion reduction aquation; Through 0.22 μ m membrane filtration degerming, obtain uniform liposome solutions;
4) with 3) add 500g mannitol, after lyophilization, remove moisture, obtain exsiccant 7-ethyl-10-hydroxycamptothecine lipidosome freeze-dried injection, be recovered to liposome, drug administration by injection after the aquation jolting before using.
Embodiment two:
1) 2kg sodium chloride carrier is dissolved in 4L water for injection, and 20g paclitaxel, 300g sphingomyelin and 0.02 μ moL/mL butylated hydroxyarisol are dissolved in 20L ethanol, add 1% activated carbon filtration depyrogenation respectively;
2), under the condition of magnetic agitation, the water for injection that is dissolved with carrier material is joined in the organic solvent that is dissolved with medicine and matrix material gradually at 30 ℃;
3) at 30 ℃; Under the condition of magnetic agitation; With 2) reduce pressure and remove organic solvent and water for injection, add the acetic acid-acetate buffer solution 10L aquation that contains the 3g polyoxyethylene hydrogenated Oleum Ricini then, through the particle diameter of the solution after the hand concussion reduction aquation; Through 0.22 μ m membrane filtration degerming, obtain uniform liposome solutions;
4) with 3) add 400g sucrose, after lyophilization, remove moisture, obtain exsiccant Paclitaxel liposome lyophilized injectable powder, be recovered to liposome, drug administration by injection after the aquation jolting before using.
Embodiment three:
1) 3kg mannitol carrier is dissolved in 4L water for injection, 30g Docetaxel, 100g cuorin and 0.03 μ moL/mL 2, and 6-di-t-butyl hydroxy-methylbenzene is dissolved in 20L ethanol, adds 1% activated carbon filtration depyrogenation respectively;
2), under the condition of magnetic agitation, the water for injection that is dissolved with carrier material is joined in the organic solvent that is dissolved with medicine and matrix material gradually at 50 ℃;
3) at 50 ℃, under the condition of magnetic agitation, with 2) reduce pressure and remove organic solvent and water for injection; Add the hydrochloric acid solution aquation 10L that contains the 5g Tween 80 then; Particle diameter through the solution after the magnetic agitation reduction aquation through 0.22 μ m membrane filtration degerming, obtains uniform liposome solutions;
4) with 3) add the 300g lactose, after lyophilization, remove moisture, obtain exsiccant Docetaxel lipidosome freeze-dried injection, be recovered to liposome, drug administration by injection after the aquation jolting before using.
Embodiment four:
1) 5kg sorbitol carrier is dissolved in 6L water for injection, and 40g ftorafur, 400g soybean lecithin are dissolved in 20L ethanol, adds 1% activated carbon filtration depyrogenation respectively, and logical nitrogen is preserved;
2), under the condition of magnetic agitation, the water for injection that is dissolved with carrier material is joined in the organic solvent that is dissolved with medicine and matrix material gradually at 60 ℃;
3) at 60 ℃; Under the condition of magnetic agitation; With 2) reduce pressure and remove organic solvent and water for injection, add the citric acid solution 10L aquation that contains the 7g polysorbas20 then, through the particle diameter of the solution after the ultrasonic reduction aquation of popping one's head in; Through 0.22 μ m membrane filtration degerming, obtain uniform liposome solutions;
4) with 3) add the 200g dextran, after lyophilization, remove moisture, obtain exsiccant ftorafur lipidosome freeze-dried injection, be recovered to liposome, drug administration by injection after the aquation jolting before using.
Embodiment five:
1) 7kg sucrose carrier is dissolved in 10L water for injection, and 17g 5-fluorouracil, 500g soybean lecithin and 0.04 μ moL/mL dilauryl thiodipropionate are dissolved in 20L ethanol, add 1% activated carbon filtration depyrogenation respectively;
2), under the condition of magnetic agitation, the water for injection that is dissolved with carrier material is joined in the organic solvent that is dissolved with medicine and matrix material gradually at 70 ℃;
3) at 70 ℃; Under the condition of magnetic agitation; With 2) reduce pressure and remove organic solvent and water for injection, add the carbonic acid-carbonate buffer solution 10L aquation that contains the 8g span 20 then, through the particle diameter of the solution after the dispersing emulsification machine reduction aquation; Through 0.22 μ m membrane filtration degerming, obtain uniform liposome solutions;
4) with 3) add the 100g trehalose, after lyophilization, remove moisture, obtain exsiccant 5-fluorouracil lipidosome freeze-dried injection, be recovered to liposome, drug administration by injection after the aquation jolting before using.
By the various kinds of drug lipidosome freeze-dried injection that the foregoing description method makes, appoint and get wherein qualified six parts, measure envelop rate, drug loading, particle diameter, bacterioscopy, and heat source check, all conformance with standard.
Overcome the Liposomal formulation poor stability that commonsense method prepares through above-mentioned practical implementation example gained lipidosome freeze-dried injection, be difficult to realize industrial shortcoming, and proved technology simple possible of the present invention that product safety is effective, steady quality.
The protection authority of application of the present invention is not limited in this; And the present invention also can other embodied under the condition that does not deviate from its basic feature; Therefore we think that it generally speaking is illustrative rather than restrictive with implementing example that the present invention has embodiment; Protection domain is confirmed according to claims rather than according to above-mentioned explanation, so all implication and the variations in the equivalency range thereof in claim all should be included in the scope of the invention.
Compare with common technology thin film-freeze drying technology
1 applied film-freeze drying technology prepares liposome, and aquation forms the process need 30min of liposome; Application technology prepares liposome, and carrier dissolves back formation liposome rapidly rapidly during aquation, and hydration process only needs 5min.
2 thin film-freeze drying technology is the most commonly used at laboratory, but because can't in tun, realize forming the thin film of homogeneous, so the difficult commercial production that realizes can only expand the scale of production through the quantity that increases Rotary Evaporators.Decompressed vector-freeze drying technology of the present invention enlarges when producing in the carrier surface film forming, only needs to increase the carrier amount and gets final product, and production equipment is not had specific (special) requirements.
3 decompressed vectors-freeze drying technology and thin film-freeze drying technology productivity ratio, the result sees table 1.
Table 1
| ? | Total inventory/kg | Total output/kg | Yield/% |
| Decompressed vector-freeze drying technology | 2.00 | 1.82 | 91 |
| Thin film-freeze drying technology | 2.00 | 1.66 | 83 |
4 see table 2 with the particle diameter comparing data after the liposome aquation of identical prescription (except that carrier) thin film-freeze drying technology and decompressed vector of the present invention-freeze drying technology preparation:
Table 2
| ? | Thin film-freeze drying technology | Decompressed vector-lyophilizing |
| Particle size/nm | 267.00 | 236.00 |
| Particle size/nm(after 8h) | 268.00 | 238.00 |
5 see table 3 with six months stability (20-25 ℃) of the liposome comparing data of identical prescription (except that carrier) thin film-freeze drying technology and decompressed vector of the present invention-freeze drying technology preparation:
Table 3
| ? | Time(month) | Appearance | pH | entrapment efficiency(%) | Particle size(nm) |
| Decompressed vector-lyophilizing | Initial | Uniform， dry | 3.22 | ﹥85 | 238.00 |
| ? | 1 | Uniform， dry | 3.22 | ﹥85 | 245.00 |
| ? | 3 | Uniform， dry | 3.20 | ﹥85 | 249.00 |
| ? | 6 | Uniform， dry | 3.14 | ﹥85 | 261.00 |
| ? | Initial | Uniform， dry | ? | ﹥80 | 263.00 |
| Thin film- |
1 | Uniform， dry | ? | ﹥80 | 271.00 |
| ? | 3 | Uniform， dry | ? | ﹥80 | 275.00 |
| ? | 6 | Uniform， dry | ? | ﹥80 | 280.00 |
Introduce the research process of this method for preparing below
Single factor of preparation technology is investigated experiment
(1) choice of Solvent
Select methanol respectively, ethanol, acetonitrile, ethyl acetate, dissolved in chloroform medicine and matrix material.Final dissolving dehydrated alcohol is as the solvent of medicine and matrix material.
(2) investigation of mixing speed
Investigated mixing speed 10,30 respectively, during 50,70,90,110,130,150,170,200 rpm, final excellent mixing speed of selecting is 170rpm, and preparation time is suitable, and when preventing that material from splashing, the carrier suspendible is also more abundant.
(3) investigation of preparation temperature
Investigated following liposome preparation temperature respectively: room temperature (20 ℃-25 ℃), 30 ℃, 40 ℃, 50 ℃, 60 ℃, 70 ℃.When preparation temperature was lower than 40 ℃, the speed of absolute ethanol volatilizes was slower, and preparation time is longer.Preparation temperature is 50 ℃, 60 ℃, in the time of 70 ℃, measure envelop rate according to method under the entrapment efficiency determination item, and the result sees table 4.Consider higher entrapment and suitable preparation time, finally select 50 ℃ as preparation temperature.
The envelop rate of the different preparation temperatures of table 4
| The preparation temperature(℃) | 50 | 60 | 70 |
| EE (%) | 85.32 | 70.69 | 59.47 |
(4) selection of aquation mode
Respectively at ultrasonic 10min; Magnetic agitation 10min; Hand 10min, every at a distance from jolting twice in 30 seconds, cross under the condition of dispersing emulsification machine 10min, cross the filter membrane of 0.8 μ m with the aquation WATER AS FLOW MEDIUMization, according to method mensuration envelop rate under the entrapment efficiency determination item, the result sees table 5.The final magnetic agitation method of selecting, the liposome encapsulation of using after this method is recombinated is higher, and application conditions is simple, more is applicable to clinical.
The envelop rate of the different aquation conditions of table 5
| The reconstituted method | Ultrasonator | magnetic stirring | Shake by hand |
| EE (%) | 68.51 | 81.72 | 80.42 |
(5) investigation of hydration time
Use aquation WATER AS FLOW MEDIUMization 5,10,15 respectively, cross the filter membrane of 0.8 μ m behind the 20min, measure envelop rate according to method under the entrapment efficiency determination item, the result sees table 6.The final optimum reorganization time of selecting 5min as liposome, the liposome encapsulation that makes is all greater than 80%.
The envelop rate of the different hydration times of table 6
| The reconstituted time(min) | 5 | 10 | 15 | 20 |
| EE (%) | 82.59 | 82.36 | 76.15 | 74.12 |
(6) investigation of hydration temperature
Get an amount of liposome powder, respectively (20 ℃-25 ℃), 35 ℃, 45 ℃; 55 ℃, 65 ℃, 75 ℃; 85 ℃ of following aquation media are recombinated, and cross the filter membrane of 0.8 μ m, and measuring the reorganization temperature according to method under the entrapment efficiency determination item is that the 45-65 ℃ of envelop rate under the condition is all greater than 80%.So when clinical use, recommending the serviceability temperature scope is 20-70 ℃, 55 ℃ of conduct reorganization of final selection temperature in this research, the liposome quality after the reorganization is higher.
Claims (8)
1. the method for preparing lipidosome of a suitable suitability for industrialized production is characterized in that decompressed vector is prepared liposome technology to combine with freeze drying technology, and its concrete steps are:
(1) carrier is dissolved in water for injection, and medicine, matrix material and stabilizing agent are dissolved in organic solvent, adds the activated carbon filtration depyrogenation respectively;
(2), under the condition of magnetic agitation, the water for injection that is dissolved with carrier material is joined in the organic solvent that is dissolved with medicine and matrix material gradually at 20-70 ℃;
(3), under the condition of magnetic agitation, organic solvent and water for injection are removed in 2 decompressions at 20-70 ℃; Add the aquation medium aquation that contains emulsifying agent then; Particle diameter through the solution after the applied external force reduction aquation through 0.22 μ m membrane filtration degerming, obtains uniform liposome solutions;
(4) add freeze drying protectant with 3, remove moisture, obtain exsiccant 7-ethyl-10-hydroxycamptothecine lipidosome freeze-dried injection, be recovered to liposome, drug administration by injection after the aquation jolting before using through lyophilization.
2. method for preparing lipidosome according to claim 1 is characterized in that, described carrier is a sodium chloride, and glucide is selected from glucose, sucrose, mannitol, the sorbitol one or more.
3. method for preparing lipidosome according to claim 1 is characterized in that described matrix material is a phospholipid, is selected from one or more mixture in sphingomyelin, phosphatidylcholine, Phosphatidylserine, the cuorin.
4. method for preparing lipidosome according to claim 1 is characterized in that, described stabilizing agent is anhydrous sodium sulfite, Vc, nitrogen, dibenzylatiooluene, alpha-tocopherol, one or more mixture in α-tocopheryl acetate, the hydroquinone.
5. method for preparing lipidosome according to claim 1 is characterized in that, described emulsifying agent is a poloxamer, one or more mixture in polyoxyethylene hydrogenated Oleum Ricini, Tweens, the spans.
6. method for preparing lipidosome according to claim 1; It is characterized in that; Described freeze drying protectant is a glucide, is selected from lactose, mannitol, sorbitol, xylitol, sucrose, trehalose, dextran, the polyvinylpyrrolidone one or more.
7. according to the method for preparing lipidosome described in the claim 1, it is characterized in that applied external force is hand concussion, ultrasonic washing unit is ultrasonic, the probe excusing from death, and magnetic agitation is crossed dispersing emulsification machine.
8. the equipment of a method for preparing lipidosome as claimed in claim 1; It is characterized in that; Be equipped with rhombohedral rotor three neck round-bottomed flasks be positioned in the magnetic agitation water-bath, three mouths of three neck round-bottomed flasks are connected with respectively like lower device: the left side mouth is vacuum orifice (1); Middle port is charge door (2), is connected with funnel when reinforced, seals with plug during preparation; The right side is discharging opening (3), seals with plug during preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110454185 CN102552142B (en) | 2011-12-30 | 2011-12-30 | Liposome preparing method suitable for industrial production |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110454185 CN102552142B (en) | 2011-12-30 | 2011-12-30 | Liposome preparing method suitable for industrial production |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102552142A true CN102552142A (en) | 2012-07-11 |
| CN102552142B CN102552142B (en) | 2013-08-28 |
Family
ID=46399613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110454185 Active CN102552142B (en) | 2011-12-30 | 2011-12-30 | Liposome preparing method suitable for industrial production |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102552142B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103622924A (en) * | 2013-12-10 | 2014-03-12 | 沈阳药科大学 | Docetaxel liposome and preparation method thereof |
| CN106214641A (en) * | 2016-08-22 | 2016-12-14 | 沈阳鑫泰格尔医药科技开发有限公司 | A kind of liposome being applicable to water soluble drug and preparation method thereof |
| CN113397978A (en) * | 2021-07-16 | 2021-09-17 | 江西科技师范大学 | System for preparing and purifying nanoliposome |
-
2011
- 2011-12-30 CN CN 201110454185 patent/CN102552142B/en active Active
Non-Patent Citations (1)
| Title |
|---|
| 叶田田等: "中心复合效应面设计法优化7-乙基-10-羟基喜树碱(SN-38) 前体脂质体处方", 《沈阳药科大学学报》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103622924A (en) * | 2013-12-10 | 2014-03-12 | 沈阳药科大学 | Docetaxel liposome and preparation method thereof |
| CN103622924B (en) * | 2013-12-10 | 2016-06-15 | 沈阳药科大学 | A kind of docetaxel liposome and preparation method thereof |
| CN106214641A (en) * | 2016-08-22 | 2016-12-14 | 沈阳鑫泰格尔医药科技开发有限公司 | A kind of liposome being applicable to water soluble drug and preparation method thereof |
| CN113397978A (en) * | 2021-07-16 | 2021-09-17 | 江西科技师范大学 | System for preparing and purifying nanoliposome |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102552142B (en) | 2013-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hong et al. | Lung cancer therapy using doxorubicin and curcumin combination: Targeted prodrug based, pH sensitive nanomedicine | |
| CN103118662B (en) | The method preparing the heterogeneous dosage form of freeze-dried instant | |
| CN102258470B (en) | Preparation of doxorubicin hydrochloride nanoliposome preparation | |
| CN106265514B (en) | A kind of doxorubicin hydrochloride magnetic nano particle and preparation method thereof | |
| WO2014101356A1 (en) | Gamabufotalin liposome, preparation method therefor and applicationthereof | |
| CN101278932A (en) | Sustained release medicinal compositions containing Zaltoprofen, preparation method and application thereof | |
| CN104667292A (en) | Preparation of reducing response type drug conjugate nanoparticle and application of reducing response type drug conjugate nanoparticle | |
| CN104224710B (en) | A kind of docetaxel nanometer micella, its preparation method and application | |
| CN103768046A (en) | Injection paclitaxel nanocrystal and preparation method thereof | |
| CN102552142B (en) | Liposome preparing method suitable for industrial production | |
| CN103622924B (en) | A kind of docetaxel liposome and preparation method thereof | |
| CN101091714A (en) | Liposome of precursor containing ginsenoside Rh2, and preparation method | |
| CN109771660A (en) | It is a kind of to respond the preparation of pectin-adriamycin/tripterine nanometer particle with pH | |
| CN110664784B (en) | Composite nano drug delivery system and application thereof in gynecological tumor treatment | |
| CN101322681B (en) | Method for preparing nano micelle formulation of anthracene nucleus antineoplastic antibiotic | |
| CN101020060A (en) | Cyclodextrin clathrate of entecavir and its prepn proces and medicinal application | |
| CN102805729A (en) | Vinflunine liposome preparation and preparation method of vinflunine liposome preparation | |
| CN102085189B (en) | Docetaxel liposome sterile lyophilized preparation and preparation method thereof | |
| CN110317281B (en) | Hyaluronic acid-g-folic acid amphiphilic polymer and application thereof | |
| CN107281500A (en) | A kind of adriamycin composite and preparation method and application | |
| CN107412781B (en) | Self-assembly drug loading system of o-nitrophenylpropionic acid paclitaxel conjugate as well as preparation method and application of self-assembly drug loading system | |
| CN102670579B (en) | Paclitaxel pharmaceutical composition and preparation method thereof | |
| CN104490772A (en) | Liver targeting taxol nanometer suspension and preparation method thereof | |
| CN101693010B (en) | Cefathiamidine prosoma liposome preparation | |
| CN108186573A (en) | It is a kind of using lipid encapsulation mesoporous silicon oxide as hydroxycamptothecin Liver targeting preparation of carrier and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20181123 Address after: 110016 No. 103, cultural road, Shenhe District, Shenyang, Liaoning Co-patentee after: Shenyang Junhong Pharmaceutical Technology Co., Ltd. Patentee after: Shenyang Pharmaceutical University Address before: 110013 No. 103 Cultural Road, Shenhe District, Shenyang City, Liaoning Province Patentee before: Shenyang Pharmaceutical University |